Skip to content

Efficacy and safety study of light therapy in the treatment of depressive episodes

Efficacy and safety study of light therapy in the treatment of depressive episodes

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056564
Enrollment
Unknown
Registered
2022-02-08
Start date
2022-02-08
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depressive episode

Interventions

bipolar depression test grop:Eco Light (5000 lux)
bipolar depression control group:Eco light(100lux)
unipolar depression test grop:Eco Light (5000 lux)
unipolar depression control grop:Eco light(100lux)

Sponsors

Beijing Anding Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for depression, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), with first episode or recurrence, without psychotic symptoms; or meet DSM-5 diagnostic criteria for bipolar disorder, depressive episode, and not accompanied by psychotic symptoms; 2. Aged 18-65 years, no gender limit; 3. The 17-item Hamilton Depression Scale (HAMD-17) score during screening and baseline period: 14-24; 4. Currently taking antidepressants or mood stabilizers, the medication regimen was not changed one week before enrollment, and the medication regimen and dosage remained unchanged during treatment; 5. Subjects can understand and comply with the study requirements, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Subjects currently or previously diagnosed with a disorder other than depressive disorder according to the MINI diagnostic criteria; 2. Subjects currently receiving MECT or other physical therapy; 3. At present, the subject has serious suicide risk, and HAMD-17 suicide risk item >=3 points; 4. Subjects with unstable physical diseases requiring medical or surgical treatment; 5. Existing or existing eye diseases, such as cataract, macular degeneration, glaucoma, retinitis pigmentosa, etc.; 6. Previous or current diagnosis of epilepsy; 7. History of drug dependence (including alcohol) within 12 months before inclusion, history of drug abuse within 1 month, or positive urine test for illicit drugs during screening; 8. Pregnant or lactating subjects.

Design outcomes

Primary

MeasureTime frame
HAMD total score subtracted;Difference in efficiency;

Secondary

MeasureTime frame
Changes in the Epworth total score on the scale;Changes in blood indexes;Changes in fatigue scale-14;The MEQ assesses changes in circadian patterns;

Countries

China

Contacts

Public ContactZhao Qian

Beijing Anding Hospital Affiliated to Capital Medical University

zqanding@ccmu.edu.cn+86 13811953687

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026